Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

NINLARO Hard capsule (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

NINLARO 2.3 mg hard capsules. NINLARO 3 mg hard capsules. NINLARO 4 mg hard capsules.

Qualitative and quantitative composition

NINLARO 2.3 mg hard capsules: Each capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate). NINLARO 3 mg hard capsules: Each capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate). ...

Pharmaceutical form

Hard capsule. NINLARO 2.3 mg hard capsules: Light pink, size 4 gelatin hard capsule, marked Takeda on the cap and 2.3 mg on the body with black ink. NINLARO 3 mg hard capsules: Light grey, size 4 gelatin ...

Therapeutic indications

NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Posology and method of administration

Treatment must be initiated and monitored under the supervision of a physician experienced in the management of multiple myeloma. Posology The recommended starting dose of ixazomib is 4 mg administered ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal ...

Special warnings and precautions for use

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional special warnings and precautions for use. Thrombocytopenia ...

Interaction with other medicinal products and other forms of interaction

Pharmacokinetic interactions CYP inhibitors Co-administration of ixazomib with clarithromycin, a strong CYP3A inhibitor, did not result in a clinically meaningful change in the systemic exposure of ixazomib. ...

Fertility, pregnancy and lactation

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional information on fertility, pregnancy and lactation. Women of ...

Effects on ability to drive and use machines

Ixazomib has minor influence on the ability to drive or use machines. Fatigue and dizziness have been observed in clinical trials. Patients should be advised not to drive or operate machines if they experience ...

Undesirable effects

As ixazomib is administered in combination with lenalidomide and dexamethasone, refer to the SmPC for these medicinal products for additional undesirable effects. Summary of the safety profile The data ...

Overdose

There is no known specific antidote for ixazomib overdose. Clinical data is limited but doses up to 12 mg have been reported in the randomised controlled trial. In the event of an overdose, monitor the ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents ATC code: L01XX50 Mechanism of action Ixazomib citrate, a prodrug, is a substance that rapidly hydrolyses under physiological ...

Pharmacokinetic properties

Absorption After oral administration, peak plasma concentrations of ixazomib were achieved at approximately one hour after dosing. The mean absolute oral bioavailability is 58%. Ixazomib AUC increases ...

Preclinical safety data

Mutagenicity Ixazomib was not mutagenic in a bacterial reverse mutation assay (Ames assay) or clastogenic in a bone marrow micronucleus assay in mice. Ixazomib was positive in an in vitro clastogenicity ...

List of excipients

NINLARO 2.3 mg hard capsules Capsule contents: Microcrystalline cellulose Magnesium stearate Talc Capsule shell: Gelatin Titanium dioxide (E171) Red iron oxide (E172) Printing ink: Shellac Propylene glycol ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 3 years.

Special precautions for storage

Do not store above 30°C. Do not freeze. Store in the original package in order to protect from moisture.

Nature and contents of container

PVC-Aluminium/Aluminium blister sealed inside a wallet pack containing one capsule. Three single blister wallet packs are packaged in one carton.

Marketing authorization holder

Takeda Pharma A/S, Dybendal Alle 10, 2630, Taastrup, Denmark

Marketing authorization number(s)

EU/1/16/1094/001 EU/1/16/1094/002 EU/1/16/1094/003

Date of first authorization / renewal of the authorization

Date of first authorisation: 21 November 2016 Date of Last Renewal: 16 September 2019

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: